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Current practice and future perspective 
of the Prenatal Genetic Service in Slovenia
Marija Volk1, Nataša Teran1, Aleš Maver1, Luca Lovrečić1, Borut Peterlin1,2
Prenatal genetic testing is under the remit of the National Health Service in Slovenia and has been included in clinical routine since 
the 1980s. Traditionally, prenatal services have consisted of karyotyping and rapid fetal aneuploidy screening to detect chromosome 
abnormalities, whereas targeted mutation testing was used for single gene disorders. Development of array comparative genomic 
hybridization and next generation sequencing allows for genome analysis at better resolution in a single experiment. While techno-
logical advances in medicine continue to evolve, increasing diagnostic accuracy and broadening the spectrum of indications, all 
these innovations require more investment along with more equipment and higher staffi  ng rations trained to use it, placing burden 
upon healthcare funding and expenditure. This prompts us to consider how to implement new techniques into the existing services 
in order to update genetic services for the 21st century. Our aim is to develop a new approach to prenatal genetic services, which 
would maximize diagnostic yield at an acceptable cost.
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INTRODUCTION
Genetic disorders represent a signifi cant share of morbidity 
and mortality in pediatric population and are an important 
public health issue. Primary and secondary prevention ge-
netic services are intended to prevent birth defects, genetic 
disorders, or disease before it occurs or before birth. New 
technologies, which could be utilized in prenatal genetic 
diagnosis, call for modifi cations and adaptations of the ex-
isting healthcare system.
In this work, we present development of the prenatal ge-
netic service, the actual conditions and our recommenda-
tions for the future under the National Health Service in 
Slovenia.
TRADITIONAL APPROACH TO PRENATAL 
GENETIC DIAGNOSIS
Prenatal genetic diagnosis has been available in Slovenia 
since 1980 (Figure 1). We started with karyotyping of amni-
otic fl uid, followed by chorionic villus sampling (CVS) in 
1984. Chromosome analysis has been off ered to pregnant 
women of advanced age (37 years or above), women with 
abnormal ultrasound scan, positive screening test (Nuchal 
Translucency, Double or Triple Hormone Test), a live-born 
child or previous pregnancy with an identifi ed chromo-
some abnormality, or because one parent carries a chromo-
somal rearrangement. Diagnostic yield of classical karyo-
type is approximately 3%, excluding Down syndrome and 
other recognizable chromosomal syndromes (1). Full chro-
mosome analysis has long been regarded as the gold 
standard for prenatal testing.
Prenatal detection of single gene disorders has been avail-
able since 1997 for couples where one parent carries an au-
tosomal dominant or X-linked disease or both parents are 
carriers of an autosomal recessive disorder. The basic mo-
lecular genetic tests, such as targeted allele-specific poly-
merase chain reaction (PCR)-based or restriction fragment 
analysis methodologies, Sanger sequencing or Southern 
blot were used to detect single gene disorders. In cases of 
unknown mutation, indirect approach by linkage analysis 
was used.
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In 1998, we introduced the use of fl uorescent in situ hybrid-
ization (FISH) in the prenatal setting. FISH allowed for detec-
tion of new categories: (a) genomic or submicroscopic mu-
tations; and (b) rapid fetal aneuploidy testing, later replaced 
by other methods (qfPCR or MLPA). Rapid fetal aneuploidy 
screening was followed by karyotype analysis.
Fluorescent in situ hybridization has fi lled the gap between 
molecular and cytogenetic diagnostic tests. In addition, 
FISH allows for analysis of metaphase chromosomes or in-
terphase nuclei. FISH probes are used to identify microdele-
tions (2), subtelomeric rearrangements (3), and origin of 
marker chromosome (4), or for simple and complex chro-
mosome rearrangements on metaphase chromosomes, 
whereas rapid fetal aneuploidy screening and evaluation of 
mosaicism can be done on interphase nuclei.
We have been using interphase FISH method for preim-
plantation genetic diagnosis (PGD) in which one or two 
blastomeres are biopsied from the early embryo for FISH 
analysis of known familial chromosome rearrangements, or 
for sex selection in X-linked monogenic disease (5, 6). 
GENOMIC TESTS IN PRENATAL GENETIC DIAGNOSIS
Now, we are facing genomic approaches. Array compara-
tive genomic hybridization (aCGH) or molecular karyotyp-
ing can scan the entire genome to detect gains and losses 
of genetic material. aCGH was introduced into our routine 
in 2014, since the output is higher comparing to classical 
karyotyping, subtelomeric MLPA analysis or FISH. Prenatal 
aCGH is routinely used in the cases of ultrasound structural 
anomalies in the fetus, including nuchal translucency >3.5 
mm, and in the case of prenatally detected chromosomal 
rearrangements using karyotyping (7, 8). Clinically relevant 
genomic imbalances are reported in 4%-7% of fetuses with 
ultrasound detected structural anomalies (7, 9, 10).
Some laboratories completely switched over their prenatal 
invasive diagnosis to aCGH (11). Apart from the fact that 
aCGH is more expensive compared to conventional karyo-
typing, there is another very important issue in prenatal di-
agnosis, i.e. how to deal with variants of unknown clinical 
signifi cance (VOUS), susceptibility loci (SL) for neurodevel-
opmental disorders and unexpected diagnoses.
In addition, aCGH has become a tool for discovering regions 
prone to genomic rearrangements (12) and for identifi ca-
tion of new deletion/duplication syndromes (13).
Moreover, Next Generation Sequencing (NGS) has radically 
changed the diagnosis of single gene disorders. It has shift-
ed focus from the pre-NGS-test diff erential diagnostic mode 
to the post-NGS-test diagnostic assessment mode (14). NGS 
allows for multi-gene analysis in a single investigation (15). 
Since the implementation of NGS in the routine genetic 
testing, we have been increasingly harnessing its diagnostic 
potential to facilitate prenatal diagnosis. Whole human ex-
ome and genome sequencing based on NGS technology 
allows for comprehensive, rapid and accessible detection of 
a variety of mutational events in a patient with suspected 
genetic disease. Quality NGS service encompasses several 
steps, including proper pre-testing clinical assessment, 
massive parallel sequencing, and orthogonal validation 
with Sanger sequencing, data analysis and exhaustive inter-
pretation. To ensure the timely and clinically valid diagnosis 
in the prenatal setting, we have been continuously optimiz-
ing each of these steps with the aim to reach 1-month refer-
ral-to-reporting time.
Recent reports indicate that exome sequencing facilitates 
prenatal genetic diagnosis (16-18). Early studies performed 
in pregnancies with ultrasound structural fetal abnormali-
ties have reported conclusive detection rate of 10% in kary-
otype- and microarray-negative cases (19, 20).
FIGURE 1. Development of the prenatal genetic service in Slovenia.
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The comprehensive nature of exome and genome se-
quencing also carries the issue of reporting variants of un-
known signifi cance, which are even more numerous than in 
microarray diagnosis. In our approach, we therefore limit 
the reporting of mutations only to those that are highly 
likely causative, which includes known pathogenic se-
quence variants and variants with certain impact (including 
non-sense and frameshift variants). Another challenge is 
the possibility of identifying unsolicited fi ndings in genes, 
which may manifest postnatally. We currently focus the 
analysis only on fi ndings pertinent to the referral diagnosis 
aiming to minimize the issue of identifying unwarranted in-
cidental fi ndings. The complexity of such a comprehensive 
and complex diagnosis in the prenatal period thus requires 
specifi c and suffi  ciently informative genetic counselling of-
fered throughout the testing process.
The impact of NGS in a single gene landscape is analogous 
to aCGH in the cytogenetic domain. However, as NGS al-
lows for detection of point mutations, small indels, CNVs 
and chromosome translocations (21), it is anticipated that 
aCGH will soon be replaced.
Since 2013, noninvasive prenatal screening (NIPS) can be of-
fered to women with high-risk pregnancy (22). NIPS analyz-
es fetal DNA molecules, which are freed into the maternal 
circulation from the placental tissue. Professional Commit-
tee of the Slovenian Association of Medical Genetics cur-
rently recommends NIPS for pregnancies at a high risk of 
common trisomies, however, there is cumulative evidence 
of comparable NIPS test characteristics in low risk pregnan-
cies. In Slovenia, NIPS is at the moment available on the pa-
tient self-pay basis. NIPS test has high specifi city (99%) and 
sensitivity (>99%) to detect fetal trisomy 21, 18, and 13, yet 
it has been shown to be slightly less specifi c and sensitive 
for sex chromosome aneuploidy detection. Positive predic-
tive value for trisomy 21 is around 45.5% (23), which is 10 
times better than the classical prenatal screening tests 
(nuchal translucency, combined screening test or triple/
quadruple screening test).
CURRENT PRACTICE AND FUTURE TRENDS
Rapid development of new technologies in medical genet-
ics increases the costs of genetic service. There is a need for 
a diff erent approach, in which indication-matched tests 
would be used to maximize diagnostic yield at an accepta-
ble cost.
Our prenatal genetic testing strategy specifi es pregnant 
women into high-risk and low-risk pregnancies (Figure 2).
High-risk pregnancy is defi ned as a positive screening test 
with a risk of 1:30 or more for chromosome abnormality, ul-
trasound detected fetal anomalies, high risk result of NIPS, 
or if one parent is carrier of a Robertsonian translocation 
involving chromosome 13 or 21, and, in addition, any other 
balanced chromosomal rearrangement or a single gene 
disorder. In these cases, rapid testing for fetal aneuploidy 
screening (qfPCR) is performed fi rst, followed by aCGH, 
when the qfPCR shows normal result. In the case of trisomy 
21, 13 or suspected chromosome mosaicism detected by 
qfPCR, karyotyping of the prenatal sample is recommended 
to clarify the chromosome constitution (Figure 2).
*  NGS is performed in selected cases only, 
as mentioned in the text









• (un)balanced chr. rearrangment
• marker chromosome
Low-risk pregnancy
• positive screening test (risk >1:300 and <1:30 for trisomy)
• maternal age >37 years
• maternal anxiety
• previous pregnancy/ child with chromosome abnormality
High-risk pregnancy
• positive screening test (risk >1:30 for trisomy)
• US detected fetal anomalies (including US detected NT >3.5 mm)
• parent is a carrier of chr. rearrangement/ single gene disorder
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Our approach considers aCGH indicated in cases of high-
risk pregnancies only, based on professional and economic 
reasons. VOUS/SL co-fi ndings can cause signifi cant emo-
tional distress for parents to be. On the other hand, resourc-
es intended for the prenatal genetic service program are 
limited.
Previously, targeted mutation testing was performed if 
there were ultrasound-detected anomalies possibly associ-
ated with a specifi c single gene disorder. Because of the ge-
netic heterogeneity of the disorders and limitations of pre-
natal ultrasound to defi ne fetal phenotype, the NGS ap-
proach will improve the performance. Since the introduction 
of NGS into our clinical routine, it has been demonstrated 
that the detection yield is far better than in other diagnostic 
tests currently in routine use. However, parents should be 
informed about the limitations of NGS and discuss it thor-
oughly at pre-test and post-test genetic counselling. A de-
fi nitive genetic diagnosis would enable informed decision-
making regarding continuation of the actual pregnancy 
and provide valuable information on the recurrence risk for 
future pregnancies.
On the other hand, low-risk pregnancies (advanced mater-
nal age without any other screening test, previous pregnan-
cy with chromosome aneuploidy and screening test with a 
risk higher than 1:300 and lower than 1:30) usually have nor-
mal qfPCR profi le and karyotype, placing substantial fi nan-
cial burden upon healthcare budget, together with an in-
creased risk of adverse pregnancy outcome because of the 
invasive procedure (CVS or amniocentesis). Similarly to 
some other European countries (24), we plan to off er rapid 
fetal aneuploidy testing as a stand-alone prenatal diagnos-
tic test to pregnant women in low-risk group. Genetic coun-
selling would be off ered to pregnant women in low-risk 
group, where they would have an opportunity to discuss 
the advantages and limitations of the tests and would be 
off ered a choice; they could opt between qfPCR and full 
chromosome karyotyping. In the case of abnormal karyo-
type, such as marker chromosome or unbalanced chromo-
some rearrangement, aCGH would be done to determine 
more accurately genomic gains or losses (Figure 2).
We are aware that rapid fetal aneuploidy testing cannot 
substitute full karyotype, since it gives information on nu-
merical aberrations of chromosome 13, 18, 21 and sex chro-
mosomes only, therefore, eventual reciprocal translocation, 
supernumerary marker chromosome or other rarer chro-
mosome fi ndings might be missed. However, in our experi-
ence, unbalanced chromosome rearrangements that could 
be detected by routine chromosome analysis are usually 
accompanied by developmental abnormalities of the fetus 
and would be detected by ultrasound examination of fetal 
morphology. It has been shown that rapid delivery of re-
sults using qfPCR as a stand-alone test for pregnancies with-
out ultrasound anomalies reduces parental anxiety (24).
At the Clinical Institute of Medical Genetics, among other ge-
netic diagnostic procedures, PGD (pre-implantation genetic 
diagnosis) is available within the remit of the Health Service 
(no out of pocket expenses) for couples at a high risk of ge-
netically disadvantaged off spring, either for chromosomal 
unbalanced rearrangement or single gene disorder.
CONCLUSION
We are witnessing rapid development of modern method-
ologies. However, technological advances are not always 
accompanied by the resources required to meet laboratory 
and medical needs. The challenge therefore is how to off er 
the best modern, rapid and appropriate medical services at 
an acceptable cost. In Slovenia, we have already introduced 
modern techniques into routine clinical practice. We are de-
veloping a strategy in the prenatal diagnostic setting to en-
sure best diagnostic yield with a combination of genetic 
tests at an aff ordable cost.
Abbreviations:
aCGH- array comparative genomic hybridization
NGS-next generation sequencing
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PCR- polymerase chain reaction
FISH- fl uorescent in situ hybridization
MLPA- multiplex ligation-dependent probe amplifi cation
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NIPS- noninvasive prenatal screening
PGD- pre-implantation genetic diagnosis
CNV- copy number variant
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S A Ž E T A K
Sadašnjost i budućnost prenatalne dijagnostike 
u Sloveniji
M. Volk, N. Teran, A. Maver, L. Lovrečić, B. Peterlin
Prenatalno genetičko testiranje u nadležnosti je Državne zdravstvene djelatnosti u Sloveniji i uključeno je u kliničku praksu od 
1980.-ih godina. Prenatalne usluge tradicionalno obuhvaćaju kariotipiziranje i brz probir na fetalne aneuploidije kako bi se otkrile 
kromosomne anomalije, dok se za poremećaje jednog gena provodilo ciljano testiranje na mutacije . Razvoj komparativne genom-
ske hibridizacije na mikropostroju i sekvenciranje sljedeće generacije omogućava analizu genoma uz bolju rezoluciju u jednom 
 testu. Dok se tehnološki napredak u medicini nastavlja poboljšavajući tako dijagnostičku točnost i šireći lepezu indikacija, ove ino-
vacije zahtijevaju sve veća ulaganja i sve više opreme te dodatno osposobljeno osoblje koje će raditi s tom opremom, što opterećuje 
zdravstvene fondove i povećava troškove. To nas potiče da razmotrimo kako uklopiti nove tehnike u postojeću službu kako bismo 
genetičke usluge prilagodili potrebama 21. stoljeća. Cilj nam je razviti nov pristup prenatalnoj genetici kojim će se postići najučinkovitiji 
rezultati uz prihvatljive troškove.
Ključne riječi: genetsko testiranje; genomske aberacije; prenatalna dijagnoza
